Torrent Pharma share price in focus after Q4 results: Nuvama, DAM Capital see upside while Nirmal Bang maintains hold rating

$TORNTPHARM share price in focus: Torrent Pharma, a leading pharma company in India, a constituent of the BSE 200, announced its financial results for the fourth quarter of FY26 on May 22. The company reported its Q4 FY26 results, with a consolidated net profit of Rs 389 crore, down 22 per cent YoY from Rs 498 crore in Q4 FY25. Despite the drop in net profit due to higher integration expenses, the company posted its highest-ever quarterly revenue at Rs 4,197 crore, a 42 per cent YoY increase. The Board has recommended a final dividend of Rs 9 per equity share of face value of Rs 5. Following its Q4 results, the brokerages have shared their mixed stance on this pharma stock. Check out their ratings if you are planning to buy, sell, hold or add this stock.